Ikarian Capital’s Pliant Therapeutics PLRX Stock Holding History

Ikarian Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90,805	Closed	-$636K	–	189
2022 Q1	$636K	Buy	90,805 +4,093	+5%	+$41.8K	0.08%	116
2021 Q4	$1.17M	Hold	86,712	–	–	0.17%	92
2021 Q3	$1.46M	Sell	86,712 -21,988	-20%	-$467K	0.1%	140
2021 Q2	$3.17M	Hold	108,700	–	–	0.26%	93
2021 Q1	$4.28M	Buy	+108,700	New	+$3.53M	0.14%	134

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Ikarian Capital's PLRX Position: Q2 2022 in Review

Ikarian Capital sold out of Pliant Therapeutics (PLRX) in Q2 2022, closing a stake of 90,805 shares — an estimated $636K sold.

Ikarian Capital first reported a position in PLRX in Q1 2021 and held it in 5 quarters. The position peaked at $4.28M in Q1 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

Ikarian Capital reported no remaining Pliant Therapeutics position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 90,805 Pliant Therapeutics shares in Q2 2022, an estimated $636K.
Ikarian Capital first reported a position in Pliant Therapeutics in Q1 2021 and held it in 5 quarters.
Ikarian Capital's Pliant Therapeutics position peaked at $4.28M in Q1 2021.
88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.